Replies to post #33554 on Biotech Values

[DewDiligence]

> NBIX – Finally, does this ring false to anyone else? PFE punts the drug for want of a food-based PK/PD trial? Very strange.<

PFE pulled out because of the separate non-approvable letter for sustained-release Indiplon, calculating that immediate-release Indiplon was not a sufficiently differentiated product to bother with. Today’s NBIX news does not have any bearing on the wisdom of PFE’s move.